LUNG News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$75.8M

Volume

236.79K

Next Earnings

October 27th

Mkt Cap

$79.5M

Volume

236.79K

Next Earnings

October 27th

Chart Financials Earnings News About Insider Filings

5 Medical Info Systems Stock to Buy for a Stable PortfolioWe have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.Zacks Investment Research · Jun 24, 2024

How Much Upside is Left in Pulmonx (LUNG)? Wall Street Analysts Think 80.3%The consensus price target hints at an 80.3% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.Zacks Investment Research · May 22, 2024

5 Medical Info Systems Stocks to Buy for Stable ReturnsWe have narrowed our search to five medical info systems stocks that have strong growth potential for 2024. These stocks are: HIMS, BFLY, ENOV, LUNG, DH.Zacks Investment Research · May 10, 2024

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on May 6, 2024 to Mehul Joshi in connection with his appointment as the Chief Financial Officer of Pulmonx in April 2024.GlobeNewswire Inc. · May 6, 2024

Wall Street Analysts See a 56.11% Upside in Pulmonx (LUNG): Can the Stock Really Move This High?The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.Zacks Investment Research · May 6, 2024

Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue EstimatesPulmonx (LUNG) delivered earnings and revenue surprises of 16.28% and 7.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 1, 2024

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024REDWOOD CITY, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2024 after the close of trading on Wednesday, May 1, 2024. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.GlobeNewswire Inc. · Apr 10, 2024

Navigating 6 Analyst Ratings For PulmonxAnalysts' ratings for Pulmonx (NASDAQ:LUNG) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 3 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 1 0 0 3M Ago 0 0 0 0 0 Analysts have recently evaluated Pulmonx and provided 12-month price targets. The average target is $16.33, accompanied by a high estimate of $17.00 and a low estimate of $14.00. This upward trend is apparent, with the current average reflecting a 6.52% increase from the previous average price target of $15.33. Breaking Down Analyst Ratings: A Detailed Examination The standing of Pulmonx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Jason Bednar Piper Sandler Maintains Overweight $17.00 $17.00 Joanne Wuensch Citigroup Raises Buy $17.00 $16.00 Larry Biegelsen Wells Fargo Lowers Equal-Weight $14.00 $16.00 Rick Wise Stifel Raises Buy $17.00 $15.00 Jason Bednar Piper Sandler Raises Overweight $17.00 $13.00 Larry Biegelsen Wells Fargo Raises Overweight $16.00 $15.00 Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to ...Full story available on Benzinga.comBenzinga · Apr 3, 2024

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerREDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company’s Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller.GlobeNewswire Inc. · Apr 2, 2024

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Mar 15, 2024

LUNGPulmonx Corporation Common Stock

LUNG

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any LUNG yet.

Related Tickers

Earnings

Mkt Cap

$75.8M

Volume

236.79K

Next Earnings

October 27th